Senzime’s next-generation TetraGraph cleared for sale in Japan

Senzime AB ( (SE:SEZI) ) has issued an announcement.

Senzime is a Swedish medical device firm known for its TetraGraph neuromuscular monitoring system, which is used to guide dosing of paralytic drugs and improve perioperative patient safety in operating rooms worldwide.
Senzime’s next-generation TetraGraph system has received regulatory clearance for sale in Japan from the PMDA, and the company has already received a first order for 80 monitors for delivery in the fourth quarter of 2025. The approval enables further commercialization in one of the world’s largest healthcare markets through Senzime’s long-standing partnership with Fukuda Denshi, which already markets integrated modules based on TetraGraph technology. With hundreds of Japanese hospitals using TetraGraph since 2019, a domestic market of roughly 15,000 operating rooms and nearly 3 million major surgeries annually, and updated clinical guidelines that reinforce quantitative neuromuscular monitoring, the clearance strengthens Senzime’s market positioning and commercial opportunity in Japan and may increase product uptake and upgrade activity among hospitals.

The most recent analyst rating on (SE:SEZI) stock is a Hold with a SEK4.50 price target. To see the full list of analyst forecasts on Senzime AB stock, see the SE:SEZI Stock Forecast page.

More about Senzime AB

Senzime is a Swedish medical device company that develops precision-based perioperative monitoring systems, notably the TetraGraph system for quantitative neuromuscular monitoring during surgery. The company focuses on hospital and operating-room markets globally, aiming to improve anesthesia management, patient safety and operational efficiency.

Average Trading Volume: 370,269

Technical Sentiment Signal: Strong Sell

Current Market Cap: SEK822.2M

Find detailed analytics on SEZI stock on TipRanks’ Stock Analysis page.